Information Provided By: 
Fly News Breaks for December 5, 2019
AUPH
Dec 5, 2019 | 07:27 EDT
Cantor Fitzgerald analyst Alethia Young views Aurinia Pharmaceuticals' data update last night for lupus nephritis as "very positive." The safety looks acceptable and the data were better than expected, showing an 18% delta versus placebo, Young tells investors in a research note. She thinks the shares will be up "at least" 300%-400% based on this news. The analyst keeps an Overweight rating on Aurinia Pharmaceuticals with a $24 price target. The stock in premarket trading is up 117%, or $9.81, to $18.20.
News For AUPH From the Last 2 Days
There are no results for your query AUPH
